R&D Trial complexity is the new normal When operationalised effectively, RBQM can support earlier risk detection and more targeted quality improvement.
R&D When metrics measure more than they improve The question to ask is not, "Are we measuring site performance?" but, "Are the metrics we collect providing actionable insights early enough?"
R&D How automation can drive a competitive advantage for CROs & ... For CROs and CDMOs, automation is key to ensuring long-term success.
R&D Navigating the new ICH E6 (R3): Key changes for sponsors These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.
R&D A playbook for effective sponsor/CRO partnership Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.
Digital Changing Faces – Digital and supplier hires from July 2024 Welcome back to Changing Faces for the month of July. Today we’re looking at CROs, CDMOs, suppliers, and tech vendors – the industry around pharma that keeps pharma ticking.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
